Search

Background: The purpose of this retrospective study was to investigate the efficacy, toxicity and mobilization rate after modified Magrath IVAC (mIVAC) chemotherapy regimen prescribed in relapsed disease (RD) or primary refractory disease (PRD) in aggressive non-Hodgkin lymphoma (NHL)., Patients and Methods: Twenty-four patients (16 males, 8 females) aged 18-59 years (median age 37 year) were analyzed. The most frequent histopathological subgroup was diffuse large B-cell lymphoma (DLCL-B) (n=21/24), 13 (54%) were considered RD and 11 (46%) PRD. The mIVAC consisted of ifosfamide (IFM), high dose cytarabine and etoposide repeated every 28 days., Results: The overall response (OR) after three cycles of mIVAC was 66. 6%. Among the patients with PRD, OR was 45.5% (5 out of 11) and with RD was 86.4%, p>0.05, however, it was observed in RD better complete response (CR) than PRD 53.8x9.1% (p<0.05). Eighty-eight percent (14 out of 16) of patients with chemosensitive disease to mIVAC underwent autologous stem cell transplantation (ASCT). The median number of collected CD34+ cells was 2.86x10(6) (range 2.17x10(6) to 4.9x10(6)). The median overall survival rate (OS) for chemosensitive to mIVAC was 16.3 months, with a median follow-up of 16 months. Grades III-IV neutropenia was observed in 85.6% per cycles and grades III-IV thrombocytopenia in 87.5%. Grades III-IV febrile neutropenia was the most common nonhematological toxicity, it occurred in 28% of the cycles and no deaths by toxicity were observed., Discussion: Although a statistic comparative study was not carried out for these 24 patients, the rate of OR to mIVAC was alike the other second-line infusion regimens. The mobilization failure rate was 57.1% and it was similar to other regimens with high dose cytarabine, but it did not limit performed ASCT.

• In pre-hematopoietic stem cell transplantation (HSCT) treated and untreated patients, there is no difference in survival. • The type of pre-HSCT treatment has a significant difference in overall survival. • Hypomethylating agents and chemotherapy in pre-HSCT treatment improve myelodysplastic syndrome survival. It has been suggested that bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be valuable in the treatment of patients with myelodysplastic syndromes (MDS). However, the influence of this approach on HSCT outcomes remains poorly defined. Therefore, our objective was to investigate the influence of treatment before HSCT in patients with MDS. We retrospectively analyzed data from the Latin American registry of 258 patients from 17 Latin American centers who underwent HSCT from 1988 to 2019. Our data showed that there was pre-HSCT. We detected no significant difference regarding the impact on overall survival of treated and untreated patients before HSCT. Despite these data, the type of previous treatment among treated patients showed a significant difference in overall survival. Treatment with hypomethylating agents together with pre-HSCT chemotherapy seems to result in better survival of the studied population. These data correspond to the first results obtained through cooperative work between various centers in Latin America comparing the different approaches to patients and reflecting their reality and challenges. Therefore, the selection of pretransplant bridge therapy should be analyzed and focus given primarily to those approaches that result in better survival of patients with MDS. [ABSTRACT FROM AUTHOR]

Introduction Although there are 70 TCs in Brazil, the HCT data reporting (DR) for a local database has not been made feasible yet; beyond that, the number of Brazilian TCs reporting for any international research database (IRD) is still small. Reporting HCT data for an IRD generates scientific information, enabling medical professionals to understand and analyze the HCT results among the TCs worldwide. This TC performed 670 HCTs (autologous and allogeneic) along 13 years. In January 2017, we started to submit data to the CIBMTR (Center for International Blood & Marrow Transplant Research). So far, 154 forms have been reported: 110 Transplant Essential Data (TED) forms and 44 Comprehensive Report Forms (CRF). The main challenges faced in the beginning were the following: understanding the data flow and identifying the data to be reported, taking part in online trainings (all offered in English language), seting up the DM team and implementing a process to help data collection. This TC's DM team consists of 2 nurses and 1 secretary working on part-time basis and partially focused on data management. DM collects data from patient's medical files, organize, scan and store data, and report follow-up and current HCT data on the FormsNet3 platform. Objective Show how this TC is structured to report data for an IRD. Introduce the strategies developed to cope with the challenges arisen along the process. Suggest alternatives to enhance the quality of the data collection. Methods Development of forms for each disease, both pre-transplantation and post-discharge. Development of auxiliary charts for the classification of disease, disease status, Karnofsky scale, degree of toxicities and graft versus host disease (all available in hard copy and e-file, rapidly and easily accessed from any device). Presentation meeting to introduce CIBMTR and sensitize the multiprofessional team to the impact of data registry on the researches, collaborating with the global scientific community to HCT advances. Creation of an exclusive e-mail to receive exams and other information about the patients involved in the project. Participation of the DM nurses in the weekly multiprofessional meeting and in the daily medical visit to the inpatients. Participation in local and international events addressed to DMs. Conclusion The events addressed to DMs are opportunities to share and exchange both experience and knowledge with DMs from other TCs worldwide and, consequently, improve DR. Additionally, the DM nurses participation in the hospital visits adds value to the data registry for it is an opportunity to check and detail information. Despite all the strategies developed, the data collection is still time consuming because part of the medical team are not fully sensitized to the importance of filling out the forms properly. However, the delay in reporting to CIBMTR is also due to the fact of DMs are not full time dedicated to the project. [ABSTRACT FROM AUTHOR]